Results 51 to 60 of about 221,174 (192)

Risk and protective factors for meningococcal disease in adolescents: matched cohort study [PDF]

, 2006
Objective: To examine biological and social risk factors for meningococcal disease in adolescents. Design: Prospective, population based, matched cohort study with controls matched for age and sex in 1:1 matching.
Stuart, J.M., Kaczmarski, E., Tully, J., Coen, P.G., Klein, N., Peckham, C., Viner, R.M., Zambon, M., Booth, C., Booy, R.   +9 more
core  

Whole genome analysis of Neisseria meningitidis isolates from invasive meningococcal disease collected in the Czech Republic over 28 years (1993-2020).

PLoS ONE, 2023
Invasive meningococcal disease belongs among the most dangerous infectious diseases in the world. Several polysaccharide conjugate vaccines against serogroups A, C, W and Y are available and two recombinant peptide vaccines against serogroup B (MenB ...
Michal Honskus, Pavla Krizova, Zuzana Okonji, Martin Musilek, Jana Kozakova   +4 more
doaj   +1 more source

Trained Immunity in Childhood Vaccination

Acta Paediatrica, EarlyView.
Trained immunity as an emerging concept in paediatric vaccinology. Trained immunity links vaccine stimuli through epigenetic and metabolic reprogramming to enhanced innate immune cell function, thereby strengthening protection against diverse pathogens while promoting adaptive immune responses through more efficient antigen presentation and co ...
ChenRongRong Cai, Lubnaa Hossenbaccus, Eva Kaufmann   +2 more
wiley   +1 more source

National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease

Expert Review of Vaccines, 2023
Introduction Invasive meningococcal disease (IMD) is a severe, life-threatening condition caused by infection with Neisseria meningitidis. Currently available vaccines offer protection against the five most common meningococcal disease-causing serogroups
Cynthia Burman, Jamie Findlow, Helen S. Marshall, Marco A.P. Safadi   +3 more
doaj   +1 more source

Meningococcal disease. Polysaccharide meningococcal vaccines. The historical aspects and the current state of vaccine development. Report 2

Биопрепараты: Профилактика, диагностика, лечение, 2018
The present article describes clinical signs of meningococcal disease. It justifies the necessity of its vaccine prevention. The article provides with the historical data on the evolution of inoculants from corpuscular inactivated vaccines to modern ...
M. V. Abramtseva, A. P. Tarasov, T. I. Nemirovskaya   +2 more
doaj  

PREVENTION OF MENINGOCOCCAL INFECTION

Медицинский совет, 2017
The article presents data on the relevance of meningococcal infection and the possibility of its prevention by vaccination. Spend a literary analysis of the efficacy and safety of vaccines against meningococcal disease. The results of the epidemiological
I. V. FRIDMAN, S. M. KHARIT
doaj   +1 more source

Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015–2016

mBio, 2021
The impact of serogroup B meningococcal (MenB) vaccines on carriage is not completely understood. Using whole-genome sequencing data, we assessed the diversity and distribution of MenB vaccine antigens (particularly FHbp) among 1,514 meningococcal ...
Henju Marjuki, How-Yi Chang, Nadav Topaz, Melissa J. Whaley, Jeni Vuong, Alexander Chen, Laurel T. Jenkins, Fang Hu, Susanna Schmink, Adam C. Retchless, Jennifer D. Thomas, Anna M. Acosta, Lucy A. McNamara, Heidi M. Soeters, Sarah Mbaeyi, Xin Wang   +15 more
doaj   +1 more source

Meningococcal Vaccination:

Delaware Journal of Public Health, 2022
Neisseria meningitidis is an aerobic, gram-negative, diplococcus bacterium that is a leading cause of meningitis and sepsis in the United States. Particularly at-risk groups include those with complement deficiencies, people using complement inhibitors, individuals with anatomic or functional asplenia, patients with HIV infection and travelers to ...
Nichols, Justin, Eppes, Stephen
openaire   +2 more sources

Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors

Internal Medicine Journal, EarlyView.
Abstract Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting.
Katherine A. Buzzard, Michael Barnett, Heidi Beadnall, Mirasol Forcadela, Lesley‐Ann Hall, Victoria G. Hall, Todd Hardy, Danny Hsu, Paul Kinsella, Mastura Monif, Sudarshini Ramanathan, Stephen W. Reddel, Sean Riminton, Douglas F. Johnson   +13 more
wiley   +1 more source

Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

Human Vaccines & Immunotherapeutics, 2018
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global ...
A. W. Dretler, N. G. Rouphael, D. S. Stephens   +2 more
doaj   +1 more source